Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

501
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
501
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Differential Tumor Immune Microenvironment Coupled With Tumor Progression Or Tumor Eradication In Hpv-antigen Expressing Squamous Cell Carcinoma (scc) Models.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Differential Tumor Immune Microenvironment Coupled With Tumor Progression Or Tumor Eradication In Hpv-antigen Expressing Squamous Cell Carcinoma (scc) Models.

Related Experiment Video

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples
07:43

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples

Published on: July 29, 2017

9.6K

Differential tumor immune microenvironment coupled with tumor progression or tumor eradication in HPV-antigen expressing squamous cell carcinoma (SCC) models.

Arpitha H Shivarudrappa1, Jessy John1, Monika Vashisht1

  • 1University of Pittsburgh Medical Center UPMC Hillman Cancer Center, Division of Hematology and Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.

Frontiers in Immunology
|July 26, 2024

View abstract on PubMed

Summary
This summary is machine-generated.
Keywords:
T cell receptorhead and neck squamous cell carcinomaimmunological heterogeneityindividualized anti-tumor immune responses

More Related Videos

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

20.1K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K

Related Experiment Videos

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples
07:43

Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples

Published on: July 29, 2017

9.6K
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

20.1K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K

Human papilloma virus (HPV) drives head and neck cancers. Researchers found that HPV-expressing tumors trigger different immune responses, with some being completely eradicated while others grow, revealing key differences in tumor immunity.

Area of Science:

  • Immunology
  • Oncology
  • Virology

Background:

  • Human papilloma virus (HPV) is a known cause of head and neck squamous cell carcinoma (HNSCC).
  • Understanding the interplay between HPV antigens and anti-tumor immunity is crucial for developing effective cancer therapies.
  • Existing research highlights the complexity of the tumor microenvironment (TME) in modulating immune responses against cancer.

Purpose of the Study:

  • To investigate the role of HPV antigens in shaping the anti-tumor immune response.
  • To establish and characterize mouse models of HPV-associated HNSCC with divergent immune outcomes.
  • To identify differences in the immune TME that correlate with tumor eradication versus progressive growth.

Main Methods:

  • Established mouse models by expressing HPV16 E6 and E7 antigens in a squamous cell carcinoma cell line.
tumor immune microenvironment
  • Utilized flow cytometry to analyze immune cell populations and activation markers within the tumor microenvironment.
  • Employed DNA sequencing to examine T cell receptor diversity and identify somatic mutations in tumor lines.

    • Main Results:

    • Two HPV antigen-expressing clones (C-225 and C-100) showed distinct outcomes: C-225 was eradicated, while C-100 grew progressively.
    • Growing tumors (C-100) had higher percentages of CD8 and CD4 tumor-infiltrating lymphocytes (TILs) but displayed upregulated exhaustion markers (PD-1, LAG-3) and impaired effector functions.
    • Eradicated tumors (C-225) were enriched with myeloid cells, including polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), while growing tumors (C-100) had more monocytic MDSCs and M2-polarized tumor-associated macrophages (TAMs).

    Conclusions:

    • Differential immune TME profiles underlie divergent anti-tumor immunity outcomes in HPV-associated HNSCC.
    • The study identified distinct immune cell compositions and functional states associated with tumor eradication versus progression.
    • These experimental models offer a platform for exploring tumor-intrinsic and host-intrinsic factors influencing immunosuppression and for identifying novel therapeutic targets in HNSCC.